How much does stem cell treatment for congestive heart failure cost?
At Stem Cell Mexico, stem cell treatment for congestive heart failure typically costs between $6,000 and $8,000 USD, depending on your heart function, the cause of heart failure, the number of cells recommended, the route of administration, the level of medical monitoring you need and the length of your stay.

Heart failure plans are usually higher than joint treatments because they involve larger cell doses, more extensive pre-treatment screening and closer observation. Your complete cost is confirmed in writing after a medical evaluation and before any deposit, and only items listed in your quote are included.
Heart failure is a serious condition, so cost should always be considered together with safety, realistic goals and how a regenerative approach fits alongside the treatment your cardiologist already provides. This guide explains each of these points.
What the price usually includes
Each quote is personalized, but a heart failure plan generally includes:
- Comprehensive medical evaluation with the doctor and stem cell specialist, reviewing your echocardiogram, ejection fraction, cardiology notes, medications and history of hospitalizations.
- Pre-treatment testing on arrival: complete blood count, comprehensive metabolic panel, urinalysis and tumor markers, plus any cardiac assessment your doctor considers necessary.
- Allogeneic mesenchymal stromal cells (MSCs) derived from donated umbilical cord tissue, prepared for your scheduled date.
- Systemic administration (usually intravenous infusion) under medical supervision.
- Extended observation, which may include one or two nights with nursing and medical monitoring, depending on your condition.
- Ground transportation, patient coordination and follow-up after you return home.
Flights, hotel nights outside the clinic and companion lodging are usually not included unless specified.
Why the price varies within the range
Type and severity of heart failure
Heart failure with reduced ejection fraction (HFrEF), mildly reduced ejection fraction and preserved ejection fraction (HFpEF) are different conditions. Your New York Heart Association (NYHA) class, which describes how much symptoms limit daily activity, and your recent stability influence the protocol and monitoring needs.
Underlying cause
Ischemic heart failure, which follows heart attacks or coronary artery disease, is the type most studied in cell therapy research. Non-ischemic causes, such as cardiomyopathies related to genetics, viral infection or toxins, may be approached differently.
Dose and frequency
Systemic heart protocols typically use more cells than local injections. Some patients consider repeated sessions over time, which affects the total investment.
Monitoring and comorbidities
Kidney disease, diabetes, arrhythmias, implanted devices and the need for longer observation can increase the level of care, and therefore the cost.
What this means: regenerative therapy alongside proven heart failure care
Heart failure treatment has advanced significantly. The European Society of Cardiology (ESC) heart failure guidelines and other international guidelines recommend a combination of medications that reduce hospitalizations and improve survival in HFrEF, often called the "four pillars": ACE inhibitors or ARNIs (sacubitril/valsartan), beta-blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors. Devices such as implantable defibrillators or cardiac resynchronization therapy, revascularization when indicated, and, in advanced cases, mechanical support or heart transplant are also part of standard care.
Cell therapy is not part of these guideline recommendations. That means any regenerative treatment should be added to optimized medical therapy, with your cardiologist informed, and never used as a reason to stop or reduce heart medications.
Heart failure in plain terms
"Heart failure" does not mean the heart has stopped. It means the heart cannot pump or fill as well as the body needs. When pumping is weak, fluid can back up into the lungs and legs, causing shortness of breath, swelling and fatigue. Ejection fraction, the percentage of blood the left ventricle pushes out with each beat, is one of the key measurements: a normal value is roughly 50 to 70 percent, while values below 40 percent indicate reduced pumping function. Natriuretic peptide blood tests (BNP or NT-proBNP), walking distance and how often you are hospitalized are other markers your doctors use to track the condition. These same markers are the ones that should be followed after any regenerative treatment.
How MSC therapy is thought to work in the heart
Early research hoped that stem cells would turn into new heart muscle. Decades of studies have shown that this happens rarely, if at all. Today, the leading explanation is that MSCs act through paracrine and immunomodulatory effects. They may:
- Reduce chronic inflammation, which is increasingly recognized as a driver of heart failure progression.
- Support the formation of small blood vessels in areas with poor blood flow.
- Limit scarring and adverse remodeling of the heart muscle.
- Protect stressed heart cells from dying.
These effects may improve the environment in which the heart works, rather than replacing damaged tissue.
What the evidence says
The research history in heart failure is long and nuanced, and it is important to distinguish between cell types and delivery routes.
Cochrane systematic review (2016): A review of 38 randomized trials with about 1,900 participants, mostly using bone marrow-derived cells in chronic ischemic heart disease and heart failure, found a reduction in long-term mortality and in some events such as non-fatal heart attacks and arrhythmias in people who received cell therapy. Ejection fraction did not change significantly.
DREAM-HF (2023): This large phase 3 trial, published in the Journal of the American College of Cardiology, studied allogeneic mesenchymal precursor cells injected directly into the heart muscle through a catheter (transendocardial delivery) in 565 patients with chronic HFrEF. The trial did not reduce its primary endpoint of recurrent heart failure hospitalizations. However, secondary analyses suggested fewer heart attacks and strokes, and potential benefit in patients with higher levels of inflammation. These findings are guiding new studies.
What this means for you: The evidence shows that cell therapy in heart failure is generally safe in trials and may influence some outcomes, especially in ischemic heart disease and inflammatory profiles, but it has not consistently improved heart pumping function or reduced hospitalizations. The cells, doses and delivery routes used in major trials differ from systemic IV umbilical cord MSC protocols, so their results should not be directly extrapolated.
Regulatory context
No stem cell therapy is approved by the FDA or the European Medicines Agency for heart failure. In Mexico, cell therapies are regulated by COFEPRIS and products must come from licensed laboratories.
Who may be a candidate
Candidacy is determined after careful review. Factors include:
- Stable heart failure on optimized medical therapy, without recent decompensation or hospitalization.
- Ejection fraction, NYHA class and the cause of heart failure.
- Kidney function, blood pressure and rhythm stability.
- No active infection and no cancer history within the past five years (documented remission required).
- The ability to travel safely and the support of your treating cardiologist.
Patients with unstable symptoms, recent heart attack, uncontrolled arrhythmias or very advanced disease may not be candidates, or may need their condition stabilized first.
What results patients commonly ask about
Will my ejection fraction go up? Some patients report better energy and exercise tolerance, and changes in ejection fraction vary between patients. Your follow-up should include an echocardiogram to measure objectively.
When might I feel a difference? If changes occur, they are usually evaluated over three to six months.
Can I stop my medications? No. Heart failure medications are essential and should only be adjusted by your cardiologist.
What can affect outcomes
- Type and cause of heart failure, and how advanced it is.
- Adherence to guideline-directed medications.
- Control of blood pressure, diabetes, kidney function and weight.
- Salt and fluid management, physical activity and cardiac rehabilitation.
- Smoking and alcohol use.
Preparing for treatment
Bring your latest echocardiogram, recent labs (including kidney function and natriuretic peptides if available) and a complete medication list. Heart medications are usually continued, but the team will review blood thinners and any drugs that require adjustment. Tell us about implanted devices, recent symptoms or weight changes. Planning a calm itinerary, with rest before and after the treatment day, helps reduce strain on the heart during travel.
Risks and limitations
IV infusions of MSCs have generally been well tolerated in clinical studies. Possible effects include fever, fatigue or headache. Because heart failure patients are sensitive to fluid volume and blood pressure changes, infusion speed and fluids are carefully managed, and monitoring is essential. Rare risks include allergic reactions, arrhythmias and thrombotic events. Results vary from person to person.
Questions to ask during your evaluation
- Given my type of heart failure, what realistic goals should I have?
- Which cell dose and route do you recommend, and what evidence supports it?
- How will you monitor me during and after the infusion?
- How will you coordinate with my cardiologist?
- What exactly is included in my $6,000 to $8,000 quote?
Bottom line
Stem cell treatment for congestive heart failure at Stem Cell Mexico typically ranges from $6,000 to $8,000 USD, reflecting larger cell doses, careful screening and extended monitoring. Research suggests possible benefits in certain patients, and treatment is designed to complement, not replace, guideline-directed heart failure care. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your heart condition, goals and medical history, and gives you a written quote before you decide.
References
- Cochrane: Fisher SA et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure, 2016 (opens in a new tab)
- Perin EC et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure (DREAM-HF). Journal of the American College of Cardiology, 2023 (opens in a new tab)
- European Society of Cardiology (ESC): 2021 Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (opens in a new tab)
